 "Morepen Laboratories surges 14% on USFDA approval for Baddi facility")
Shares of Morepen Laboratories have surged 14% to Rs 36.20 per share on the National Stock Exchange (NSE) in intra-day trade on back of heavy volumes after the company announced that it has received United States Food and Drug Administration (USFDA) approval for both its bulk drugs manufacturing facilities situated in Himachal Pradesh.
“While the Baddi facility has got US FDA approval for the manufacture of bulk drug "Atorvastatin Calcium", a Cholesterol reducing drug, the Masulkhana facility has recently got the nod for manufacturing an anti-asthma bulk drug "Montelukast Sodium" for export to the US market,” Morepen Laboratories said in a press release.
It is significant to note here that the US market size for these two bulk drugs viz. Atorvastatin Calcium and Montelukast Sodium is approximately Rs 50 billion and Rs 20 billion respectively. The two APIs collectively contributes around Rs 1.50 billion annual revenue to the company's topline and constitutes 44% of the company's total API business, it added.
At 01:43 pm; the stock was trading 11% higher at Rs 35.30 on the BSE, as compared to 0.39% rise in the S&P BSE Sensex. The trading volumes on the counter jumped more than four-fold with a combined 4.98 million equity shares changed hands on the NSE.
“While the Baddi facility has got US FDA approval for the manufacture of bulk drug "Atorvastatin Calcium", a Cholesterol reducing drug, the Masulkhana facility has recently got the nod for manufacturing an anti-asthma bulk drug "Montelukast Sodium" for export to the US market,” Morepen Laboratories said in a press release.
It is significant to note here that the US market size for these two bulk drugs viz. Atorvastatin Calcium and Montelukast Sodium is approximately Rs 50 billion and Rs 20 billion respectively. The two APIs collectively contributes around Rs 1.50 billion annual revenue to the company's topline and constitutes 44% of the company's total API business, it added.
At 01:43 pm; the stock was trading 11% higher at Rs 35.30 on the BSE, as compared to 0.39% rise in the S&P BSE Sensex. The trading volumes on the counter jumped more than four-fold with a combined 4.98 million equity shares changed hands on the NSE.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%